{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:04:46Z","timestamp":1789131886605,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.jaad.2016.07.042","type":"journal-article","created":{"date-parts":[[2016,10,26]],"date-time":"2016-10-26T08:47:31Z","timestamp":1477471651000},"page":"81-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":112,"title":["Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-\u03b1 inhibitors versus methotrexate"],"prefix":"10.1016","volume":"76","author":[{"given":"Jashin J.","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Gu\u00e9rin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murali","family":"Sundaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Dea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Cloutier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parvez","family":"Mulani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jaad.2016.07.042_bib1","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2147\/TCRM.S2740","article-title":"Moderate and severe plaque psoriasis: cost-of-illness study in Italy","volume":"4","author":"Colombo","year":"2008","journal-title":"Ther Clin Risk Manag"},{"issue":"13","key":"10.1016\/j.jaad.2016.07.042_bib2","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","volume":"33","author":"Perk","year":"2012","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.jaad.2016.07.042_bib3","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1001\/archdermatol.2009.94","article-title":"Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality","volume":"145","author":"Prodanovich","year":"2009","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2016.07.042_bib4","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/bjd.12002","article-title":"Association of psoriasis with stroke and\u00a0myocardial infarction: meta-analysis of cohort studies","volume":"167","author":"Xu","year":"2012","journal-title":"Br\u00a0J Dermatol"},{"issue":"14","key":"10.1016\/j.jaad.2016.07.042_bib5","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of myocardial infarction in patients with psoriasis","volume":"296","author":"Gelfand","year":"2006","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.jaad.2016.07.042_bib6","article-title":"Psoriasis and cardiovascular disease: epidemiological studies","volume":"58","author":"Ahlehoff","year":"2011","journal-title":"Dan Med Bull"},{"issue":"Suppl 3","key":"10.1016\/j.jaad.2016.07.042_bib7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/jdv.12162","article-title":"Psoriasis, cardiovascular events, cancer risk and alcohol use: evidence-based recommendations based on systematic review and expert opinion","volume":"27","author":"Richard","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.jaad.2016.07.042_bib8","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2796.2012.02593.x","article-title":"Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study","volume":"273","author":"Ahlehoff","year":"2013","journal-title":"J Intern Med"},{"issue":"16","key":"10.1016\/j.jaad.2016.07.042_bib9","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1093\/eurheartj\/ehr285","article-title":"Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish Nationwide Cohort Study","volume":"33","author":"Ahlehoff","year":"2012","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.jaad.2016.07.042_bib10","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-4632.2012.05584.x","article-title":"Cardiovascular aspects of psoriasis: an updated review","volume":"52","author":"Pietrzak","year":"2013","journal-title":"Int J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2016.07.042_bib11","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.amjmed.2009.08.022","article-title":"Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis","volume":"123","author":"Kimball","year":"2010","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.jaad.2016.07.042_bib12","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.jpeds.2011.03.006","article-title":"The association of psoriasis and elevated blood lipids in overweight and obese children","volume":"159","author":"Koebnick","year":"2011","journal-title":"J Pediatr"},{"key":"10.1016\/j.jaad.2016.07.042_bib13","first-page":"1","article-title":"Risk of myocardial infarction in psoriasis patients: a retrospective cohort study","author":"Wu","year":"2014","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"10.1016\/j.jaad.2016.07.042_bib14","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/jdv.12768","article-title":"Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort","volume":"29","author":"Ahlehoff","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"10.1016\/j.jaad.2016.07.042_bib15","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1038\/jid.2013.149","article-title":"Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis","volume":"133","author":"Samarasekera","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2016.07.042_bib16","doi-asserted-by":"crossref","first-page":"775.e1","DOI":"10.1016\/j.amjmed.2011.03.028","article-title":"Attributable risk estimate of severe psoriasis on major cardiovascular events","volume":"124","author":"Mehta","year":"2011","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.jaad.2016.07.042_bib17","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1365-2133.2010.09941.x","article-title":"Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the UK","volume":"163","author":"Abuabara","year":"2010","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2016.07.042_bib18","doi-asserted-by":"crossref","first-page":"e000062","DOI":"10.1161\/JAHA.113.000062","article-title":"Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies","volume":"2","author":"Armstrong","year":"2013","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"10.1016\/j.jaad.2016.07.042_bib19","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1038\/jid.2012.112","article-title":"Chronic skin-specific inflammation promotes vascular inflammation and thrombosis","volume":"132","author":"Wang","year":"2012","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2016.07.042_bib20","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jaad.2004.06.017","article-title":"Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis","volume":"52","author":"Prodanovich","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.07.042_bib21","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.amjcard.2011.06.054","article-title":"Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease","volume":"108","author":"Micha","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jaad.2016.07.042_bib22","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaad.2013.09.020","article-title":"The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies: from the Medical Board of the National Psoriasis Foundation","volume":"70","author":"Hugh","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2016.07.042_bib23","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/1759720X11436239","article-title":"Protective effect of methotrexate in patients with rheumatoid arthritis and cardiovascular comorbidity","volume":"4","author":"Marks","year":"2012","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"11","key":"10.1016\/j.jaad.2016.07.042_bib24","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1001\/archdermatol.2012.2502","article-title":"Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis","volume":"148","author":"Wu","year":"2012","journal-title":"Arch Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2016.07.042_bib25","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1001\/jama.2013.276749","article-title":"Tumor necrosis factor inhibitors and myocardial infarction in psoriasis","volume":"310","author":"Wu","year":"2013","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.jaad.2016.07.042_bib26","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1002\/art.22809","article-title":"Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register","volume":"56","author":"Dixon","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.jaad.2016.07.042_bib27","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jaad.2008.02.040","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics","volume":"58","author":"Gottlieb","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2016.07.042_bib28","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1529-8019.2010.01313.x","article-title":"Can early treatment with biologicals modify the natural history of comorbidities?","volume":"23","author":"Vena","year":"2010","journal-title":"Dermatol Ther"},{"issue":"3","key":"10.1016\/j.jaad.2016.07.042_bib29","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/rheumatology\/keq316","article-title":"Tumour necrosis\u00a0factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic\u00a0literature review","volume":"50","author":"Westlake","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2016.07.042_bib30","series-title":"Health research data for the real world: the MarketScan databases","first-page":"b28","author":"Adamson","year":"2008"},{"issue":"11","key":"10.1016\/j.jaad.2016.07.042_bib31","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"10.1016\/j.jaad.2016.07.042_bib32","doi-asserted-by":"crossref","unstructured":"Nurmohamed MTT, Bao Y, Signorovitch J, Mulani PM, Furst DE. Use of anti-TNF therapy is associated with reduced cardiovascular event risk in rheumatoid arthritis. In: 2012 annual meeting of EULAR. Vol. 71. Berlin, Germany; 2012:Abstract OP0002.\u2013Abstract OP0002.","DOI":"10.1136\/annrheumdis-2012-eular.1685"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096221630593X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096221630593X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:41:54Z","timestamp":1759272114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096221630593X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S019096221630593X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2016.07.042","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-\u03b1 inhibitors versus methotrexate","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2016.07.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}